The goal of BP to keep large profit platform drugs going over what should be best patient care is always a concern. Also the outsize influence of BP through having much larger resources and outsized FDA influence could also help maintain this status quo.

The other issue is that in patients for whom Keytruda would like likely be of benefit, would it be ethical and/or permitted to withhold keytruda and only give them leronlimab based on animal data even if the patient requested it. Of course if keytruda is not known to be of benefit in a cancer, this wouldn't be an issue and also wouldn't be a threat to keytruda.